Access cutting-edge hypertension treatment through this early phase 1 clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Minneapolis location
Preparing your pre-screening questions…
Access hypertension specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hypertension treatment provided free
Check if you qualify for this hypertension clinical trial in Minneapolis, MN
No-Cost Study Care
Local to Minneapolis
Convenient for MN residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce CVD events, including incident HF. SGLT2 is a glucose transport protein in the kidneys. Inhibition of this protein results in glucosuria and lower serum blood sugar. The SGLT2i medications were initially approved to treat type 2 diabetes (T2D). In 2015, Zinman et al. published the first large randomized clinical trial (RCT) demonstrating a lower composite CVD outcome in adults with T2D treated with empagliflozin compared to placebo (HR 0.85, 95% CI 0.74-0.99). In the specific case of empagliflozin, the hazard ratio was 0.75 (95% CI 0.65-0.86) for HFrEF 8 and 0.79 (95% CI 0.69-0.90) for HFpEF using a treatment dose of 10mg daily. The purpose of this placebo-controlled, double-blinded, randomized pilot study is to investigate the effect of empagliflozin on left atrial (LA) function in 80 patients who are at risk for heart failure. Participants will be randomized 1:1 to either intake of a 10mg empagliflozin oral tablet or a matching placebo once daily.
Sponsor: University of Minnesota
Yes, this clinical trial (NCT06507657) has an active research site in Minneapolis, MN that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for hypertension treatment options in Minneapolis, MN, this clinical trial (NCT06507657) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Minneapolis research site is actively enrolling participants for this early phase 1 clinical trial. You'll receive care from experienced hypertension specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all hypertension clinical trials near you to find additional studies recruiting in your area.
See all hypertension clinical trials recruiting in Minneapolis — not just this study.
Browse Hypertension Trials in Minneapolis →